A Phase 2 interventional study of AG-013736 in Carcinoma, Renal Cell, sponsored by Pfizer. Completed at 18 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-06-05.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies testing axitinib in Carcinoma, Renal Cell — 11 open to participants now, 15 under way, 1 of them phase 3. Axitinib · Carcinoma, Renal Cell.
Among the 41 studies testing axitinib in Carcinoma, Renal Cell, this one is the 12th largest by enrollment, is the only one that started in 2007, is one of 29 in phase 2, and was the 2nd registered.
2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.
Browse Carcinoma, Renal Cell studies →11 of the 41 studies testing axitinib in Carcinoma, Renal Cell are open now, in 7 countries. Recruiting first, the newest first:
Hebei Medical University Fourth Hospital · Sites in China
Ages 18+
Stephanie Berg · Sites in United States
Ages 18+
Tianjin Medical University Second Hospital · Sites in China
Ages 18+
Gustave Roussy, Cancer Campus, Grand Paris · Sites in Austria, Czechia, France and 1 more country
Ages 18+
Peking University Cancer Hospital & Institute · Sites in China
Ages 18–80
By country, each count listing its studies:
Axitinib: first FDA approval 2012 (INLYTA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 31 · Phase 3 5
First in 2006; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 64 is above the median of 43 across 1,566 interventional studies indexed under Carcinoma, Renal Cell.
Median enrollment 40 across the 41 interventional studies. Of the 19 that completed or were terminated, 14 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 41 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
80 studies in Carcinoma, Renal Cell by Pfizer: 1 open now, 1 under way, none of them phase 3. Of 74 finished, 54 (73%) have results posted.
Among the 80 studies in Carcinoma, Renal Cell by Pfizer, this one is the 19th largest by enrollment of the 40 interventional ones that give a count, is one of 6 that started in 2007, is one of 11 in phase 2, and was the 18th registered.
Pfizer’s Carcinoma, Renal Cell studies by the year they started, since 2002.
2 of the studies testing axitinib in Carcinoma, Renal Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07159191Peking Union Medical College HospitalEnvafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma | 2027-02-20 |
| NCT07123090Stephanie BergA Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma | 2027-10-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 41 studies testing axitinib in Carcinoma, Renal Cell, from their registry updates:
Among Pfizer’s 80 in Carcinoma, Renal Cell:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To investigate objective tumor response of AG-013736 for metastatic Renal Cell Cancer (mRCC)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: AG-013736
AG-013736 5 mg BID will be administered orally on continuous schedule. Cycle length is 28 days. If the drug is well tolerated at 5 mg BID, the dose of AG-013736 may be titrated to 7 mg BID and then to a maximum of 10 mg BID. Number of cycles: until progression or unacceptable toxicity develops.
Objective Response Rate (Percentage of Participants With Complete Response [CR] or Partial Response [PR]): Independent Review Committee Assessment
Percentage of participants with objective response based assessment of confirmed CR or confirmed PR by the Independent Review Committee, according to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0). CR was defined as the disappearance of all target and nontarget lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the longest diameters of the targeted lesions. CR and PR had to be documented on 2 occasions separated by at least 4 weeks.
Time frame: Up to 765 days of treatment at the data cut-off date
Objective Response Rate (Percentage of Participants With Complete Response [CR] or Partial Response [PR]): Investigators Assessment
Percentage of participants with objective response based assessment of confirmed CR or confirmed PR by the investigator, according to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0). CR was defined as the disappearance of all target and nontarget lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the longest diameters of the targeted lesions. CR and PR had to be documented on 2 occasions separated by at least 4 weeks.
Time frame: Up to 765 days of treatment at the data cut-off date
Progression-Free Survival (PFS)
Time in months from start of study treatment to first documentation of objective tumor progression or death due to any cause whichever comes first. PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 30.44. Tumor progression was determined from radiological image (where data meet the criteria for progressive disease \[PD\]).
Time frame: Up to 1709 days of treatment
Time to Tumor Progression (TTP)
Time in months from start of study treatment to first documentation of objective tumor progression. TTP was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 30.44. Tumor progression was determined from radiological image (where data meet the criteria for progressive disease \[PD\]).
Time frame: Up to 1709 days of treatment
Duration of Response
Time in months from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.44. DR was calculated for the subgroup of participants with a confirmed objective tumor response.
Time frame: Start of first confirmed CR or PR to the date of the first event (PD or death) or the last tumor assessment, whichever came first, assessed up to 1709 days.
Overall Survival (OS)
OS was defined as the time from date of first dose of AG-013736 to date of death due to any cause. Subjects in whom death is not reported will have their event time censored on the last date the subject is known to be alive.
Time frame: Up to 2002 days (maximum duration of treatment plus follow-up observation)
Number of Participants Analyzed for Population Pharmacokinetics of AG-013736
Population pharmacokinetic analysis of AG-013736 is conducted by combining current study data with other AG-013736 studies.
Time frame: Cycle 1 Day 1 (2 hours after morning dose); Cycles 3, 5, and 7 Day 1 predose and 2 hours post morning dose
Plasma Concentration of Soluble Vascular Endothelial Growth Factor Receptor 1 (s-VEGFR1)
Time frame: Cycle 1 Day 1 predose, Day 1 of Cycle 2 to Cycle 7, and end of treatment/discontinuation (assessed up to 1709 days)
Plasma Concentration of Soluble Vascular Endothelial Growth Factor Receptor 2 (s-VEGFR2)
Time frame: Cycle 1 Day 1 predose, Day 1 of Cycle 2 to Cycle 7, and end of treatment/discontinuation (assessed up to 1709 days)
Plasma Concentration of Soluble Vascular Endothelial Growth Factor Receptor 3 (s-VEGFR3)
Time frame: Cycle 1 Day 1 predose, Day 1 of Cycle 2 to Cycle 7, and end of treatment/discontinuation (assessed up to 1709 days)
Plasma Concentration of Soluble Stem Cell Factor Receptor (s-KIT)
Time frame: Cycle 1 Day 1 predose, Day 1 of Cycle 2 to Cycle 7, and end of treatment/discontinuation (assessed up to 1709 days)
Plasma Concentration of Vascular Endothelial Growth Factor (VEGF)
Time frame: Cycle 1 Day 1 predose, Day 1 of Cycle 2 to Cycle 7, and end of treatment/discontinuation (assessed up to 1709 days)
Number of Participants With Adverse Events
Number of participants with any adverse events, adverse events graded as Common Terminology Criteria (CTCAE) for Adverse Events Version 3.0 Grade 3 or higher , serious adverse events, or adverse events resulted in discontinuation.
Time frame: Up to 1709 days of treatment plus 28-days follow-up
| Milestone | AG-013736 |
|---|---|
| Started | 64 |
| Completed | 5 |
| Not completed | 59 |
| Withdrew: Adverse event | 16 |
| Withdrew: Objective progression or relapse | 42 |
| Withdrew: Global deterioration of health status | 1 |
Percentage of participants with objective response based assessment of confirmed CR or confirmed PR by the Independent Review Committee, according to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0). CR was defined as the disappearance of all target and nontarget lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the longest diameters of the targeted lesions. CR and PR had to be documented on 2 occasions separated by at least 4 weeks.
| percentage of participants | AG-013736 |
|---|---|
| Objective Response Rate (Percentage of Participants With Complete Response [CR] or Partial Response [PR]): Independent Review Committee Assessment | 50.0 (37.2 to 62.8) |
Percentage of participants with objective response based assessment of confirmed CR or confirmed PR by the investigator, according to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0). CR was defined as the disappearance of all target and nontarget lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the longest diameters of the targeted lesions. CR and PR had to be documented on 2 occasions separated by at least 4 weeks.
| percentage of participants | AG-013736 |
|---|---|
| Objective Response Rate (Percentage of Participants With Complete Response [CR] or Partial Response [PR]): Investigators Assessment | 54.7 (41.7 to 67.2) |
Time in months from start of study treatment to first documentation of objective tumor progression or death due to any cause whichever comes first. PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 30.44. Tumor progression was determined from radiological image (where data meet the criteria for progressive disease \[PD\]).
| months | AG-013736 |
|---|---|
| Independent Review Committee Assessment | 11.0 (9.2 to 12.0) |
| Investigators Assessment | 12.0 (9.2 to 14.8) |
Time in months from start of study treatment to first documentation of objective tumor progression. TTP was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 30.44. Tumor progression was determined from radiological image (where data meet the criteria for progressive disease \[PD\]).
| months | AG-013736 |
|---|---|
| Independent Review Committee Assessment | 11.0 (9.2 to 12.0) |
| Investigators Assessment | 12.0 (9.2 to 14.8) |
Time in months from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.44. DR was calculated for the subgroup of participants with a confirmed objective tumor response.
| months | AG-013736 |
|---|---|
| Independent Review Committee Assessment (n=33) | 11.1 (8.2 to 13.7) |
| Investigators Assessment (n=36) | 12.8 (7.7 to 17.5) |
OS was defined as the time from date of first dose of AG-013736 to date of death due to any cause. Subjects in whom death is not reported will have their event time censored on the last date the subject is known to be alive.
| months | AG-013736 |
|---|---|
| Overall Survival (OS) | 37.3 (28.6 to 49.9) |
Population pharmacokinetic analysis of AG-013736 is conducted by combining current study data with other AG-013736 studies.
No measurements were reported for this outcome.
| pg/mL | AG-013736 |
|---|---|
| Cycle 1 Day 1 (n=64) | 83.10 (44.3 to 215) |
| Cycle 2 Day 1 (n=63) | 63.60 (0 to 190) |
| Cycle 3 Day 1 (n=60) | 68.20 (36.4 to 936) |
| Cycle 4 Day 1 (n=59) | 69.20 (33.5 to 119) |
| Cycle 5 Day 1 (n=57) | 62.90 (0 to 125) |
| Cycle 6 Day 1 (n=52) | 62.00 (32.1 to 119) |
| Cycle 7 Day 1 (n=48) | 57.75 (0 to 101) |
| End of Treatment/Discontinuation (n=55) | 76.60 (0 to 2780) |
| pg/mL | AG-013736 |
|---|---|
| Cycle 1 Day 1 (n=64) | 8900.0 (2620 to 13400) |
| Cycle 2 Day 1 (n=63) | 6040.0 (2760 to 12600) |
| Cycle 3 Day 1 (n=60) | 5980.0 (3340 to 11600) |
| Cycle 4 Day 1 (n=59) | 6030.0 (3310 to 11600) |
| Cycle 5 Day 1 (n=57) | 5880.0 (3140 to 10400) |
| Cycle 6 Day 1 (n=52) | 5790.0 (3160 to 9920) |
| Cycle 7 Day 1 (n=48) | 5395.0 (3620 to 10400) |
| End of Treatment/Discontinuation (n=55) | 6540.0 (2870 to 12600) |
| pg/mL | AG-013736 |
|---|---|
| Cycle 1 Day 1 (n=64) | 20250.0 (2060 to 132000) |
| Cycle 2 Day 1 (n=63) | 12000.0 (1990 to 45700) |
| Cycle 3 Day 1 (n=60) | 13100.0 (2090 to 47700) |
| Cycle 4 Day 1 (n=59) | 13800.0 (0 to 39100) |
| Cycle 5 Day 1 (n=57) | 16700.0 (0 to 38100) |
| Cycle 6 Day 1 (n=52) | 15550.0 (5200 to 39800) |
| Cycle 7 Day 1 (n=48) | 13750.0 (0 to 38200) |
| End of Treatment/Discontinuation (n=55) | 22300.0 (0 to 54500) |
| pg/mL | AG-013736 |
|---|---|
| Cycle 1 Day 1 (n=64) | 39050.0 (24800 to 73700) |
| Cycle 2 Day 1 (n=63) | 35000.0 (21800 to 64000) |
| Cycle 3 Day 1 (n=60) | 37300.0 (20700 to 65000) |
| Cycle 4 Day 1 (n=59) | 38100.0 (20100 to 64300) |
| Cycle 5 Day 1 (n=57) | 39800.0 (24600 to 70700) |
| Cycle 6 Day 1 (n=52) | 41400.0 (23500 to 65900) |
| Cycle 7 Day 1 (n=48) | 42400.0 (23100 to 62000) |
| End of Treatment/Discontinuation (n=55) | 40600.0 (22200 to 72000) |
| pg/mL | AG-013736 |
|---|---|
| Cycle 1 Day 1 (n=64) | 63.40 (26.4 to 361) |
| Cycle 2 Day 1 (n=63) | 162.00 (31.5 to 856) |
| Cycle 3 Day 1 (n=60) | 137.00 (26.3 to 723) |
| Cycle 4 Day 1 (n=59) | 145.00 (21.9 to 514) |
| Cycle 5 Day 1 (n=57) | 155.00 (24.3 to 554) |
| Cycle 6 Day 1 (n=52) | 184.50 (21.3 to 743) |
| Cycle 7 Day 1 (n=48) | 180.00 (46 to 762) |
| End of Treatment/Discontinuation (n=55) | 121.00 (15.6 to 617) |
Number of participants with any adverse events, adverse events graded as Common Terminology Criteria (CTCAE) for Adverse Events Version 3.0 Grade 3 or higher , serious adverse events, or adverse events resulted in discontinuation.
| participants | AG-013736 |
|---|---|
| Any adverse events | 64 |
| Any serious adverse events | 21 |
| Any Grade-3 or -4 adverse events | 58 |
| Any Grade-5 adverse events (= death) | 1 |
| Discontinuation due to adverse events | 16 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AG-013736 | — | 21/64 (32.8%) | 64/64 (100%) |
| Event | AG-013736 |
|---|---|
| DiarrhoeaGastrointestinal disorders | 3/64 |
| VomitingGastrointestinal disorders | 2/64 |
| PneumoniaInfections and infestations | 2/64 |
| DehydrationMetabolism and nutrition disorders | 2/64 |
| HypertensionVascular disorders | 2/64 |
| Acute myocardial infarctionCardiac disorders | 1/64 |
| Angina unstableCardiac disorders | 1/64 |
| Myocardial infarctionCardiac disorders | 1/64 |
| HyperthyroidismEndocrine disorders | 1/64 |
| Duodenal stenosisGastrointestinal disorders | 1/64 |
| Event | AG-013736 |
|---|---|
| HypertensionVascular disorders | 56/64 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 48/64 |
| DiarrhoeaGastrointestinal disorders | 44/64 |
| FatigueGeneral disorders | 36/64 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 34/64 |
| ProteinuriaRenal and urinary disorders | 33/64 |
| HypothyroidismEndocrine disorders | 31/64 |
| Decreased appetiteMetabolism and nutrition disorders | 27/64 |
| NasopharyngitisInfections and infestations | 25/64 |
| NauseaGastrointestinal disorders | 22/64 |
| Age, Customized(Participants) | AG-013736 |
|---|---|
| <18 | 0 |
| 18-44 | 6 |
| 45-64 | 30 |
| >= 65 | 28 |
| Sex: Female, Male(Participants) | AG-013736 |
|---|---|
| Female | 20 |
| Male | 44 |
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Dec 2007 to primary completion in Feb 2010, 26 months.
Results were first posted in Mar 2012, 2 years 1 month after primary completion.
Of 47 industry-sponsored phase 2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 52. This study's 26 months is below that.
Counting every sponsor, half of 231 studies reached it within 59 months; a quarter within 33 and three quarters within 94.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Axitinib